Clopidogrel is safer than ticagrelor in regard to bleeds: A closer look at the PLATO trial

International Journal of Cardiology

Volumn 168, Issue 3, 2013, Pages 1739-1744

  Dinicolantonio, James J ^a   D'Ascenzo, Fabrizio ^b   Tomek, Ales ^c   Chatterjee, Saurav ^d,e   Niazi, Asfandyar K ^f   Biondi Zoccai, Giuseppe ^g  

^a Wegmans Pharmacy   (United States)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^d BROWN UNIVERSITY   (United States)

^e Providence VAMC   (United States)

^f SHIFA COLLEGE OF MEDICINE   (Pakistan)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Bleeds; Clopidogrel; Hemorrhagic events; Ticagrelor

Indexed keywords

ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; TICAGRELOR;

APNEA; BLEEDING; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CORONARY ARTERY BYPASS GRAFT; CYANOSIS; DIARRHEA; DISEASE CLASSIFICATION; DIZZINESS; DRUG SAFETY; DYSPNEA; ECCHYMOSIS; EPISTAXIS; FAINTNESS; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; GLOMERULUS FILTRATION RATE; HEART ATRIUM FLUTTER; HEART MUSCLE ISCHEMIA; HEMATOMA; HEMATURIA; HIGH RISK PATIENT; HUMAN; HYPOXIA; INCIDENCE; KIDNEY FAILURE; LIVER DISEASE; LUNG EMBOLISM; OPERATION DURATION; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; PRESYNCOPE; PRIORITY JOURNAL; RECTUM HEMORRHAGE; RESPIRATORY FAILURE; RETROPERITONEAL HEMATOMA; REVIEW; SICK SINUS SYNDROME; SUBCUTANEOUS HEMORRHAGE; SUBDURAL HEMATOMA; THORAX DRAINAGE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOEMBOLISM; VERTIGO;

BLEEDS; CLOPIDOGREL; HEMORRHAGIC EVENTS; TICAGRELOR;

ADENOSINE; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMORRHAGE; HUMANS; INCIDENCE; PURINERGIC P2Y RECEPTOR ANTAGONISTS; TICLOPIDINE;

EID: 84885663662     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.06.135     Document Type: Editorial

References (13)

1. L. Wallentin, R.C. Becker, A. Budaj, C.P. Cannon, H. Emanuelsson, and C. Held Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
2. FDA ticagrelor review of complete response - drug approval package http://www.accessdata.fda.gov/drugsatfda-docs/nda/2011/022433Orig1s000TOC.cfm Administration UFaD 2011 US Department of Health and Human Services Silver Spring, MD
3. M. Cohen Expanding the recognition and assessment of bleeding events associated with antiplatelet therapy in primary care Mayo Clin Proc 84 2 Feb 2009 149 160
4. V.L. Serebruany, J.J. DiNicolantonio, and M.M. Can Mortality in the TRACER and ATLAS ACS 2 trials: two more reasons to audit vital records in PLATO Cardiology 123 2012 11 14
5. J.J. DiNicolantonio, M.M. Can, and V.L. Serebruany Lost in follow-up rates in TRACER, ATLAS ACS 2, TRITON and TRA 2P trials: challenging PLATO mortality rates Int J Cardiol 164 3 Apr 15 2013 255 258
6. J.J. DiNicolantonio, and V.L. Serebruany Exploring the reduction in myocardial infarction in the PLATO trial: which patients benefited on ticagrelor vs. clopidogrel? Int J Cardiol 165 3 May 25 2013 396 397
7. V.L. Serebruany Viewpoint: paradoxical excess mortality in the PLATO trial should be independently verified Thromb Haemost 105 5 May 2011 752 759
8. J.J. DINicolantonio, and V.L. Serebruany Exploring the ticagrelor-statin interplay in the PLATO trial Cardiology 124 2 2013 105 107
9. J.J. DiNicolantonio, and V.L. Serebruany Comparing the safety of ticagrelor versus clopidogrel: insights from the FDA reports Ther Adv Cardiovasc Dis 7 1 2013 5 9
10. J.J. DiNicolantonio, and V.L. Serebruany Challenging the FDA black box warning for high aspirin dose with ticagrelor in patients with diabetes Diabetes 62 3 Mar 2013 669 671
11. J.J. DiNicolantonio, and V.L. Serebruany Comparing ticagrelor versus clopidogrel in patients with a history of cerebrovascular disease: a net clinical harm? Stroke 43 12 Dec 2012 3409 3410
12. J.J. DiNicolantonio, and G. Biondi-Zoccai Challenging ticagrelor's claimed reduction in the rate of definite stent thrombosis versus clopidogrel: insights from the FDA reports Int J Cardiol 2013 10.1016/j.ijcard.2013.04.149
13. J.J. DiNicolantonio, V.L. Serebruany, and A. Tomek Refuting the ticagrelor-aspirin black box warning: and proposing a ticagrelor early-PCI black box warning. Int J Cardiol 168 3 May 30 2013 1721 1723